A Leading Chinese Biotech Company, Quality Cornerstones, Take the Deal

Founder

Kemp Dolliver, CFA

Cherrystone Hill Research

Equity Capital Markets

<p>3SBio, China's leading biotech company, posted H1 results in line with pre-deal expectations. The recent acquisition of Zhejiang Wansheng broadens the current product line and adds several early-stage compounds to the R&amp;D pipeline. The shares look more attractive now, having declined 13% since the listing to 22x estimated 2016E EPS.&nbsp;</p>

3SBio, China's leading biotech company, posted H1 results in line with pre-deal expectations. The recent acquisition of Zhejiang Wansheng broadens the current product line and adds several early-stage compounds to the R&amp;D pipeline. The shares look more attractive now, having declined 13% since the listing to 22x estimated 2016E EPS.&nbsp;

QUICKNOTE: H1 Results in Line, R&D Pipeline Expands

3SBio Inc

QUICKNOTE: H1 Results in Line, R&D Pipeline Expands